How does vascepa affect cholesterol levels compared to other meds?

Short answer
- Vascepa (icosapent ethyl) mainly lowers triglycerides. It can modestly raise LDL cholesterol in some people, with variable effects on HDL and non-HDL cholesterol. It’s not a primary LDL-lowering medicine.

How Vascepa affects cholesterol vs other meds
- Triglycerides (TG)
- Vascepa: Typically reduces TG by about 25%–40% (varies by baseline TG and individual response).
- Statins: May modestly lower TG, but not as much as Vascepa.
- Fibrates (e.g., fenofibrate, gemfibrozil): Often lower TG more strongly than statins; used when TG needs substantial lowering.
- Niacin: Lowers TG, but usage has declined due to side effects.
- PCSK9 inhibitors: Do not meaningfully lower TG; mainly reduce LDL-C.
- EPA+DHA omega-3s (Lovaza, Vascepa-like products that include DHA): TG lowering is similar, but LDL-C effects can differ (DHA-containing products may raise LDL-C more in some people).

- LDL cholesterol
- Vascepa: Can cause a modest increase in LDL-C in some people (often small, around a few percent; results vary).
- Statins: Primary LDL-C-lowering therapy (large reductions, depending on dose and baseline risk).
- Fibrates: Generally neutral to modestly affect LDL-C; not relied on for LDL lowering.
- Niacin: Lowers LDL-C (also raises HDL); not used as commonly due to side effects.
- PCSK9 inhibitors: Large LDL-C reductions (often 50%–70%).
- EPA+DHA omega-3s: LDL-C impact is variable and can be an increase for some people.

- HDL and non-HDL
- Vascepa: HDL effects are variable; non-HDL-C may decrease a bit if TG drop is substantial, but LDL-C rise can offset that.
- Other meds: Vary by agent (e.g., statins mainly affect LDL-C; niacin raises HDL; fibrates can modestly raise HDL and lower TG).

Practical takeaways
- Vascepa is best used for patients with high triglycerides who are already on a statin or other lipid-lowering therapy, to reduce ASCVD risk through TG lowering (as shown in REDUCE-IT).
- If LDL-C is a concern (or rises with Vascepa), your clinician may look at optimizing statin therapy, adding ezetimibe or a PCSK9 inhibitor, or considering other strategies to keep LDL-C in target range.
- Always monitor your lipid panel after starting Vascepa to see how your TG, LDL-C, and HDL-C respond.

If you’re weighing Vascepa against other options, tell me your specific lipid numbers, current meds, and ASCVD risk factors, and I can outline a more tailored comparison.